Indianapolis – October 19, 2026 -- Half of pediatric ulcerative colitis (UC) patients who responded to Eli Lilly's Omvoh (mirikizumab-mrkz) were in clinical remission at Week 52, meeting the primary endpoint of the Phase 3 SHINE-2 study. Lilly (NYSE: LLY) says Omvoh is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric UC, and it plans to submit the data to global regulators for a potential label expansion.

Indianapolis – October 18, 2026 -- Eli Lilly and Company (NYSE: LLY) will present first Phase 1 data for its investigational FRα-targeting antibody-drug conjugate sofetabart mipitecan (Sofe-M) in platinum-sensitive ovarian cancer (PSOC) at the European Society for Medical Oncology (ESMO) Congress, October 23–27 in Madrid, alongside updated data across lung, thyroid and breast cancer programs.

Indianapolis – October 15, 2026 -- Eli Lilly and Company (NYSE: LLY) will publish its third-quarter 2026 financial results on October 29, 2026, and will discuss the numbers on a conference call the same day.

Lilly schedules a 10 a.m. Eastern call for investors and media

The conference call begins at 10 a.m. Eastern time. Lilly will use it to detail the company's financial performance for the quarter with the investment community and media.

Indianapolis – October 15, 2026 -- More than one in four ulcerative colitis (UC) patients (27.7%) treated with Eli Lilly and Company's Omvoh (mirikizumab-mrkz) achieved comprehensive disease control at one year, compared with 14% on placebo, according to a post hoc analysis of the LUCENT-2 trial.

In the VIVID-1 Crohn's disease trial, 20.4% of Omvoh-treated patients reached corticosteroid-free deep remission, versus 2% on placebo. Lilly will present both analyses at United European Gastroenterology (UEG) Week 2026.

New York – October 05, 2026 -- A new multisector coalition launched the 30x30x50 Brain Challenge, pledging to cut stroke incidence by 30 percent and increase primary-care cognitive screening by 50 percent across 30 global cities by 2031.

Indianapolis – October 02, 2026 -- The U.S. Food and Drug Administration has approved an expanded indication for Eli Lilly and Company's Jaypirca (pirtobrutinib), clearing the non-covalent BTK inhibitor as a first-line treatment for adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) without 17p deletion.

New York – – October 02, 2026 -- The American Institute of Chemical Engineers (AIChE) will honor 16 chemical engineering leaders with its 2026 Institute and Board of Directors' Awards, the organization's highest professional recognition, at the AIChE Annual Meeting in Minneapolis, Minnesota, November 8-12.

Indianapolis – – September 30, 2026 -- Eli Lilly and Company (NYSE: LLY) reported that its oral GLP-1 therapy Foundayo (orforglipron) reduced cardiovascular death risk by 53% and all-cause death risk by 57% compared with insulin glargine in the Phase 3 ACHIEVE-4 trial, the largest and longest study of the medicine in type 2 diabetes to date.

Indianapolis – September 30, 2026 -- Eli Lilly and Company (NYSE: LLY) said its EBGLYSS (lebrikizumab-lbkz) monotherapy met the primary and secondary endpoints of the Phase 3b ADtouch study at Week 16, with more than half of treated patients achieving clear or almost clear skin on hands and feet (HF-IGA 0/1), the company disclosed ahead of the European Academy of Dermatology and Venereology Congress in Vienna, running Sept. 30-Oct. 3.

Indianapolis – September 30, 2026 -- Eli Lilly and Company (NYSE: LLY) reported that its investigational triple hormone receptor agonist retatrutide produced an average weight loss of 49.6 lbs (20.8%) over 80 weeks at the 12 mg dose in patients with type 2 diabetes and obesity, with more than half of participants no longer meeting BMI criteria for obesity. The Phase 3 TRIUMPH-2 results were presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan and simultaneously published in The Lancet.